This distinct trend pattern between patients with lung cancer and non-lung cancer may be due to the development and adoption of lung cancer–specific medium panels, which assessed multiple guideline-approved gene targets simultaneously in EGFR, BRAF, KRAS, HRAS, NRAS, ALK, ERBB2, MET, ALK, ROS1, RET, and NTRK1 genes. The gene discussed is ROS1; the disease is lung carcinoma.